 |
|
|
| |
Elbasvir/Grazoprevir in Children Aged 3 to <18 Years With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: Final Results From
an Iterative Pharmacokinetic Modeling Study
|
| |
| |
AASLD 2020 Nov 11-16
Reported by Jules Levin
Stefan Wirth1; Regino P. Gonzalez-Peralta2; Robert H. Squires3; Frauke Mutschler4; Thomas Lang5; Malgorzata Pawlowska6; Wojciech Sluzewski7; Ewa Majda-Stanislawska8; Bjorn Fischler9; William Balistreri10; Maureen M. Jonas11; Niviann Blondet12; Philip Rosenthal13; Naim Alkhouri14; Rene Romero15; Anjana Grandhi16; Patricia Castronuovo16; Luzelena Caro16; Daniel Rosenbloom16; Lihong Du16; Barbara A. Haber16
1Helios Medical Center, Witten/Herdecke University, Wuppertal, Germany; 2AdventHealth for Children and AdventHealth Transplant Institute, Orlando, FL, USA; 3University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; 4Hannover Medical School, Hannover, Germany; 5Klinikum Starnberg, Starnberg, Germany; 6Collegium Medicum,
Nicolaus Copernicus University, Bydgoszcz, Poland; 7Karol Marcinkowski University of Medical Sciences, Poznan, Poland; 8Medical University of Lodz, Lodz, Poland; 9Karolinska Institutet CLINTEC and Karolinska University Hospital, Stockholm, Sweden; 10Cincinnati Children's Hospital, Cincinnati, OH, USA; 11Boston Children's Hospital, Boston, MA, USA; 12Seattle Children's Hospital and the University of Washington, Seattle, WA, USA; 13University of California, San Francisco, San Francisco, CA, USA; 14Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 15Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA; 16Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
